Name: UMIN ID:
Unique ID issued by UMIN | UMIN000003935 |
---|---|
Receipt number | R000004731 |
Scientific Title | To evaluate the efficacy of XELOX+Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy |
Date of disclosure of the study information | 2010/08/01 |
Last modified on | 2022/10/11 16:18:17 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2010/07/21 17:03:44 | ||
2 | Update | 2012/02/01 10:18:57 | Last name of contact person Last name of contact person Organization Organization Division name Division name Address Address Organization Organization Division name Institute Institute Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
3 | Update | 2013/11/25 14:16:31 | Key exclusion criteria Key exclusion criteria |
|
4 | Update | 2013/11/25 14:17:13 | Email |
|
5 | Update | 2015/01/21 13:15:33 | Recruitment status |
|
6 | Update | 2016/07/06 16:38:22 | UMIN ID1 |
|
7 | Update | 2021/01/27 19:29:41 | Recruitment status Date of IRB Anticipated trial start date Last follow-up date |
|
8 | Update | 2021/05/25 15:33:10 | UMIN ID2 |
|
9 | Update | 2022/10/11 16:11:45 | Recruitment status |
|
10 | Update | 2022/10/11 16:13:59 | Key exclusion criteria |
|
11 | Update | 2022/10/11 16:18:17 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Name of primary person or sponsor Organization Organization Organization Address Address Tel |